Sort   by:  
 Page size 
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Cell NAMPTi treatment)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7251 | MetaboLights
ProteomicsTMTpro-18plex analysis of MM1.S cells treated with PROTACs
MM1.S cells were treated with DMSO, 0.3 µM Po-P, 0.3 µM Le-P, 0.3 µM F-P, 0.3 µM Cl-P, or 0.3 µM F3C-P for 16 h in three biological replicates. The cells were lysed in 100 µL guanidine buffer (6 M guanidine-HCl, 100 mM HEPES-NaOH, pH 7.5, 10 mM TCEP, 40 mM chloroacetamide). After heating and sonicat...
ORGANISM(S): Homo Sapiens (human) 
2023-07-22 | PXD037178 | JPOST Repository
ProteomicsTMTpro-18plex analysis of NTERA-2 cells treated with PROTACs
NTERA-2 cells were treated with DMSO, 0.3 µM Po-P, 0.3 µM Le-P, 0.3 µM F-P, 0.3 µM Cl-P, or 0.3 µM F3C-P for 16 h in three biological replicates. The cells were lysed in 100 µL guanidine buffer (6 M guanidine-HCl, 100 mM HEPES-NaOH, pH 7.5, 10 mM TCEP, 40 mM chloroacetamide). After heating and sonic...
ORGANISM(S): Homo Sapiens (human) 
2023-07-22 | PXD037179 | JPOST Repository
UnknownDepression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial.
Not available
S-EPMC8329781 | biostudies-literature
UnknownBRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
Not available
S-EPMC4907358 | biostudies-literature
UnknownPrognostic evaluation of quick sequential organ failure assessment score in ICU patients with sepsis across different income settings.
Not available
S-EPMC10804657 | biostudies-literature
UnknownNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Not available
S-EPMC4630206 | biostudies-literature
UnknownGenetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
Not available
S-EPMC3107565 | biostudies-literature
UnknownHaplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Not available
S-EPMC3196382 | biostudies-literature
UnknownCommon variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.
Not available
S-EPMC3733139 | biostudies-literature
Sort   by:  
 Page size